Back to Search Start Over

Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis : 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial

Authors :
Ostergaard, Mikkel
van Vollenhoven, Ronald F.
Rudin, Anna
Hetland, Merete Lund
Heiberg, Marte Schrumpf
Nordstrom, Dan C.
Nurmohamed, Michael T.
Gudbjornsson, Bjorn
Ornbjerg, Lykke Midtboll
Boyesen, Pernille
Lend, Kristina
Horslev-Petersen, Kim
Uhlig, Till
Sokka, Tuulikki
Grondal, Gerdur
Krabbe, Simon
Lindqvist, Joakim
Gjertsson, Inger
Glinatsi, Daniel
Kapetanovic, Meliha Crnkic
Aga, Anna-Birgitte
Faustini, Francesca
Parmanne, Pinja
Lorenzen, Tove
Giovanni, Cagnotto
Back, Johan
Hendricks, Oliver
Vedder, Daisy
Rannio, Tuomas
Grenholm, Emma
Ljosa, Maud Kristine
Brodin, Eli
Lindegaard, Hanne
Soderbergh, Annika
Rizk, Milad
Kastbom, Alf
Larsson, Per
Uhrenholt, Line
Just, Soren Andreas
Stevens, David J.
Laurbjerg, Trine Bay
Bakland, Gunnstein
Olsen, Inge Christoffer
Haavardsholm, Espen A.
Lampa, Jon
Ostergaard, Mikkel
van Vollenhoven, Ronald F.
Rudin, Anna
Hetland, Merete Lund
Heiberg, Marte Schrumpf
Nordstrom, Dan C.
Nurmohamed, Michael T.
Gudbjornsson, Bjorn
Ornbjerg, Lykke Midtboll
Boyesen, Pernille
Lend, Kristina
Horslev-Petersen, Kim
Uhlig, Till
Sokka, Tuulikki
Grondal, Gerdur
Krabbe, Simon
Lindqvist, Joakim
Gjertsson, Inger
Glinatsi, Daniel
Kapetanovic, Meliha Crnkic
Aga, Anna-Birgitte
Faustini, Francesca
Parmanne, Pinja
Lorenzen, Tove
Giovanni, Cagnotto
Back, Johan
Hendricks, Oliver
Vedder, Daisy
Rannio, Tuomas
Grenholm, Emma
Ljosa, Maud Kristine
Brodin, Eli
Lindegaard, Hanne
Soderbergh, Annika
Rizk, Milad
Kastbom, Alf
Larsson, Per
Uhrenholt, Line
Just, Soren Andreas
Stevens, David J.
Laurbjerg, Trine Bay
Bakland, Gunnstein
Olsen, Inge Christoffer
Haavardsholm, Espen A.
Lampa, Jon
Publication Year :
2023

Abstract

Background The optimal first-line treatment in early rheumatoid arthritis (RA) is debated. We compared clinical and radiographic outcomes of active conventional therapy with each of three biological treatments with different modes of action. Methods Investigator-initiated, randomised, blinded-assessor study. Patients with treatment-naive early RA with moderate-severe disease activity were randomised 1:1:1:1 to methotrexate combined with (1) active conventional therapy: oral prednisolone (tapered quickly, discontinued at week 36) or sulfasalazine, hydroxychloroquine and intra-articular glucocorticoid injections in swollen joints; (2) certolizumab pegol; (3) abatacept or (4) tocilizumab. Coprimary endpoints were week 48 Clinical Disease Activity Index (CDAI) remission (CDAI <= 2.8) and change in radiographic van der Heijde-modified Sharp Score, estimated using logistic regression and analysis of covariance, adjusted for sex, anticitrullinated protein antibody status and country. Bonferroni's and Dunnet's procedures adjusted for multiple testing (significance level: 0.025). Results Eight hundred and twelve patients were randomised. Adjusted CDAI remission rates at week 48 were: 59.3% (abatacept), 52.3% (certolizumab), 51.9% (tocilizumab) and 39.2% (active conventional therapy). Compared with active conventional therapy, CDAI remission rates were significantly higher for abatacept (adjusted difference +20.1%, p<0.001) and certolizumab (+13.1%, p=0.021), but not for tocilizumab (+12.7%, p=0.030). Key secondary clinical outcomes were consistently better in biological groups. Radiographic progression was low, without group differences. Conclusions Compared with active conventional therapy, clinical remission rates were superior for abatacept and certolizumab pegol, but not for tocilizumab. Radiographic progression was low and similar between treatments.

Details

Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1428125679
Document Type :
Electronic Resource
Full Text :
https://doi.org/10.1136.ard-2023-224116